Primary Stenting of the Superficial Femoral Artery in Intermittent Claudication Improves Health Related Quality of Life, ABI and Walking Distance: 12 Month Results of a Controlled Randomised Multicentre Trial
| Autor: | H. Lindgren, P. Qvarfordt, M. Åkesson, S. Bergman, A. Gottsäter, I. Jansson, E. Litterfeldt, T. Fransson, A. Öjersjö, A. Hilbertson, T. Röjlar, G. Gruber, T. Hörer, T. Larzon, T. Jonasson, C. Strandberg, P. Andersson, L. Lundell, A. Svensson, M. Warvsten |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.medical_treatment Walking Disease 030204 cardiovascular system & hematology Peripheral Arterial Disease 03 medical and health sciences Walking distance 0302 clinical medicine Predictive Value of Tests Surveys and Questionnaires Occlusion medicine Humans Ankle Brachial Index Prospective Studies 030212 general & internal medicine Aged Sweden Health related quality of life Exercise Tolerance Superficial femoral artery business.industry Endovascular Procedures Stent Recovery of Function Intermittent Claudication Middle Aged Intermittent claudication Femoral Artery Treatment Outcome medicine.anatomical_structure Quality of Life Physical therapy Female Stents Surgery medicine.symptom Ankle Cardiology and Cardiovascular Medicine business |
| Zdroj: | European Journal of Vascular and Endovascular Surgery. 53:686-694 |
| ISSN: | 1078-5884 |
| Popis: | Invasive treatment of intermittent claudication (IC) because of severe atherosclerotic stenosis or occlusion in the superficial femoral artery (SFA) is controversial. This prospective randomised trial was performed to assess the impact on health related quality of life (HRQoL) of primary stenting with nitinol self expanding stents compared with best medical treatment alone in patients suffering from stable IC due to SFA disease.One hundred patients with stable IC caused by SFA disease from seven Swedish hospitals treated with best medical treatment (BMT) were randomised to either the stent (n = 48) or the control (n = 52) group. Change in HRQoL assessed by the Short Form 36 Health Survey (SF-36) and EuroQoL 5 dimensions (EQ5D) 12 months after treatment was the primary outcome measure. Improvement in the Walking Impairment Questionnaire (WIQ), ankle brachial index (ABI), and walking distance were secondary outcomes.HRQoL improved significantly. In the stent group the following SF-36 domains improved: Physical Function, 19 points (p .001); Bodily Pain, 14 points (p = .001); General Health, 6 points (p = .019); Vitality, 10 points (p = .004); Physical Component Summary, 6.5 points (p .001); EQ5D, 0.14 points (p = .008); and WIQ 22 points (p .001). They were unchanged in the control group. Both ABI (from 0.58 ± 0.11 to 0.86 ± 0.19, p .001, in the stent group and from 0.63 ± 0.17 to 0.70 ± 0.20, p = .005, in the control group) and walking distance (WD) (from 171 ± 90 meters to 613 ± 381 meters, p .001, in the stent group and from 209 ± 106 m to 335 ± 321 meters, p = .012, in the control group) improved, and at 12 months both the ABI (p .001) and the WD (p = .001) were higher in the stent group.In patients with IC caused by lesions in the SFA, the addition of primary stenting to BMT was associated with significant improvement in HRQoL, ABI, and walking distance after 12 months follow-up compared with BMT alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect